CoChat
Sign Up
Cited by 66Retinoids in leukemia and cellular processesPeroxisome Proliferator-Activated ReceptorsNanoparticle-Based Drug Delivery

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid

Estey, E, Thall, PF, Mehta, K, Rosenblum, M, Brewer, T Jr, Simmons, V, Cabanillas, F, Kurzrock, R, Lopez-Berestein, G·1996·Blood
DOI 10.1182/blood.v87.9.3650.bloodjournal8793650
Open this paper in CoChat — free account

Abstract

We administered liposome-encapsulated all-trans retinoic acid (L-ATRA) to 48 patients with refractory hematologic malignancies using an every- other-day schedule for 28 days and doses of 15 to 175 mg/m2. In 19 patients, pharmacology studies were conducted after the first (day 1) and seventh (day 15) doses. In contrast to the decline in tretinoin concentration seen within 3 to 4 days of administration of daily oral ATRA, there were no differences between the area under the curve (AUC) of tretinoin concentration versus time on day 1 and day 15 (P = .98, Wilcoxon signed-rank test). Peak day 1 concentrations after 15 mg/m2 were higher than those reported after 45 mg/m2 oral ATRA. Six patients with relapsed acute promyelocytic leukemia (APL) were treated. Three, each in first relapse and at least year from the last exposure to oral ATRA, achieved a complete response (CR). Disease recurred in two (one at 3 months despite maintenance L-ATRA and similarity in tretinoin AUC on days 1 and 85, and the other at 5 months, 2 months after discontinuation of L-ATRA) and the third was transplanted 1 month into CR. The three nonresponders were in at least a second relapse and failed to respond to oral ATRA before or immediately after receiving L- ATRA. Severe toxicity developed in three of eight patients treated at 175 mg/m2 (joint pains in two, skin in one). The maximum tolerated dose (MTD) was determined to be 140 mg/m2, at which dose grade 2 toxicity (primarily headache and skin) occurred in eight of eight patients, but grade 3 to 4 toxicity in none. Compared with oral ATRA, L-ATRA apparently results in greater exposure to tretinoin and for a longer time.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood.v87.9.3650.bloodjournal8793650

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 16 references

Cited by

Sorted by citations

See all 66

Related

See all

Metadata

Authors
Estey, E., Thall, P., Mehta, K., Rosenblum, M., Brewer, T. J., Simmons, V, Cabanillas, F., Kurzrock, R., & Lopez-Berestein, G.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
ORCID
Venue
Blood
Publisher
American Society of Hematology
Published
1996-05-01
Volume
87
Issue
9
Pages
3650-3654
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood.v87.9.3650.bloodjournal8793650
OpenAlex
W2413626681
Cited by
66
References
16
Citations by year
2023: 1 · 2021: 1 · 2020: 1 · 2018: 2 · 2015: 2 · 2013: 2 · 2012: 1
FWCI
1.39
Type
journal article
Language
en
Open access
closed
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Funders
U.S. Food and Drug Administration (FDA-01-000923)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
all-trans retinoic acid, pharmacokinetics, refractory hematologic malignancies, acute promyelocytic leukemia, relapsed APL, dose escalation, maximum tolerated dose, drug toxicity, drug exposure
MeSH terms
Drug Carriers, Hematologic Diseases, Humans, Liposomes, Neoplasms, Recurrence, Tretinoin, Leukemia, Myeloid, Acute

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review